Total raised
$11.1M
Last: Equity crowdfunding 2024-02
Stage
Series A
Founded
2015
Headcount
10
HQ
Jerusalem
Sector
Health Tech & Life Sciences
About
Betalin Therapeutics seeks to eliminate the need for insulin injections and glucose testing in diabetes patients with its proprietary transplanted Engineered Micro Pancreas (EMP). The EMP technology helps create connective tissue that enables the body's beta cells to function properly and produce adequate and functional insulin.
Betalin Therapeutics licensed the novel EMP technology developed at the Hebrew University of Jerusalem, Israel, in an exclusive worldwide agreement in 2015. The Hebrew University continues to partner with Betalin Therapeutics to support the research and development.
Funding history · 3 rounds · $11.1M total
2024-02
Equity crowdfunding
Undisclosed
2022-01
Series A
$565K
2019-04
Seed
$2.5M
Sectors & technology
Primary sector
Health Tech & Life Sciences
Sub-sectors
Health Tech & Life SciencesPharma & Medical BiotechnologyBiomaterials & Tissue Engineering
Technologies
Materials & SubstancesImplantsBiologicalsCells
Target customers
Healthcare & Life SciencesHealthcareProvidersPatients
Business model
B2B2C
Highlights
1 PatentsVerified
Tags
bioconvergencediabetescell-therapybiological-therapyregenerative-medicinebiopharmaceuticalbiotechnologychronic-patientstreatments